Antibody-Drug Conjugates (ADCs) are a class of targeted drugs composed of a payload linked to an mAbs (antibody) that is designed to specifically release their payload at a tumor site.
The History of ADC Drugs Development began with the first ADC clinical trial in 1983. As of October, the FDA has approved 15 different ADCs as seen in Table 1.
Drug
Trade name
Maker
Condition
Approval Year
Gemtuzumab ozogamicin
Mylotarg
Pfizer/Wyeth
relapsed acute myelogenous leukemia (AML)
2000, 2017
Brentuximab vedotin
Adcetris
Seattle Genetics, Millennium/Takeda
relapsed HL and relapsed sALCL
2011
Trastuzumab emtansine
Kadcyla
Genentech, Roche
HER2-positive metastatic breast cancer (mBC)
2013
Inotuzumab ozogamicin
Besponsa
CD22-positive B-cell precursor acute lymphoblastic leukemia
2017
Moxetumomab pasudotox
Lumoxiti
Astrazeneca
hairy cell leukemia (HCL)
2018
Polatuzumab vedotin-piiq
Polivy
diffuse large B-cell lymphoma (DLBCL)
2019
Enfortumab vedotin
Padcev
Astellas/Seattle Genetics
urothelial cancer
Trastuzumab deruxtecan
Enhertu
AstraZeneca/Daiichi Sankyo
HER2-positive breast cancer
Sacituzumab govitecan
Trodelvy
Immunomedics
triple-negative breast cancer (mTNBC)
2020
Belantamab mafodotin-blmf
Blenrep
GlaxoSmithKline (GSK)
multiple myeloma
Cetuximab saratolacan
Akalux
RakutenMedical
Head and neck cancer
Loncastuximab tesirine-lpyl
Zynlonta
ADC Therapeutics
Large B-cell lymphoma
2021
Disitamab vedotin
Aidixi
RemeGen
HER2+ gastric carcinoma
Tistotumab vedotin-tftv
Tivdak
Seagen
Cervical cancer
Mirvetuximab soravtansine-gyxn
ELAHERE
ImmunoGen, Inc.
Ovarian Cancer
2022
Two of the latest ADCs to be approved, Tivdak and ELAHERETM were developed with linkers cleavable dipeptide val-cit and sulfo-SPDB linkers respectively.
As a leading bioconjugation linker supplier, BroadPharm offers a wide variety of ADC Linkers to empower your advanced research.